A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT00811993. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase Ib Study To Evaluate The Safety Of Combining IGF-1R Antagonist R1507 With Multiple Standard Chemotherapy Drug Treatments In Patients With Advanced Malignancies
Study identification
- NCT ID
- NCT00811993
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 104 participants
Conditions and interventions
Conditions
Interventions
- RG1507 Drug
- RO1507 Drug
- bevacizumab [Avastin] Drug
- capecitabine [Xeloda] Drug
- carboplatin Drug
- cetuximab Drug
- docetaxel Drug
- erlotinib [Tarceva] Drug
- etoposide Drug
- gemcitabine Drug
- irinotecan Drug
- mFOLFOX6 Drug
- paclitaxel Drug
- pemetrexel Drug
- sorafenib Drug
- temozolomide Drug
- trastuzumab [Herceptin] Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2009
- Primary completion
- Nov 30, 2012
- Completion
- Nov 30, 2012
- Last update posted
- Nov 1, 2016
2009 – 2012
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tucson | Arizona | 85724 | — |
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Santa Monica | California | 90025 | — |
| Not listed | Washington D.C. | District of Columbia | 20007 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | Chapel Hill | North Carolina | 27514 | — |
| Not listed | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00811993, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2016 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00811993 live on ClinicalTrials.gov.